Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/1/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Donald Hayden?

Donald J. Hayden

Chairman

Insmed Incorporated

HQ Phone:  (908) 977-9900

Direct Phone: (804) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Insmed Incorporated

10 Finderne Avenue Building 10

Bridgewater, New Jersey,08807

United States

Company Description

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE™, or liposomal amikacin for inhalation, for at least two iden... more

Find other employees at this company (289)

Background Information

Employment History

Key Executive Roles

Global Pharmaceutical Corporation


Director

Otsuka America Pharmaceutical , Inc.


Lead Independent Director

AMICUS THERAPEUTICS INC


Director of New Business Development and Planning

USA Pharmaceutical Group


Chairman

Vitae Pharmaceuticals , Inc.


Executive Vice President and President, Americas

Bristol-Myers Squibb Company


Affiliations

REGENXBIO Inc.

Chairman


Governance Committee

Member


Nominations

Member


WindMIL Therapeutics , Inc.

Board Member


Prospect Venture Partners

Senior Advisor


Gloucester Pharmaceuticals Inc

Chairman


DesignWrite , Inc.

Board Member


Alvine Pharmaceuticals Inc

Board Member


Executive Chairman of Azelon Pharmaceuticals , Chairman

Board Member


Satori Pharmaceuticals Incorporated

Board Member


Cancer Care , Inc.

Board of Trustees Member


Cambridge , MA - February 20 , 2007 -

Vice Chairman


Dimension Therapeutics, Inc.

Board Member


Transave , Inc.

Chairman


Education

BA

Harvard University


Masters of Business Administration degree

Indiana University


Web References(90 Total References)


BOARD OF DIRECTORS - Insmed

www.insmed.com [cached]

Donald J. Hayden, Jr.
Donald J. Hayden, Jr. Chairman of the Board Mr. Hayden has been the non-Executive Chairman of our Board since December 2010, except for the period from May 2012 to September 2012, when he acted as our Executive Chairman during a transition of senior level management. He previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. He previously served as chairman of the board for Vitae Therapeutics (Nasdaq: VTAE) from 2006 to 2016 until its acquisition by Allergan plc (NYSE: AGN). Mr. Hayden currently serves as chairman of the board of REGENXBIO (Nasdaq: RGNX) as well as lead independent director of Amicus Therapeutics (Nasdaq: FOLD). Mr. Hayden also serves on the board of directors for the privately-held company WindMIL Therapeutics. Mr. Hayden also serves as a director of Otsuka America Pharmaceuticals, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Masters of Business Administration degree from Indiana University. Mr. Hayden is a member of the Nominations and Governance Committee.


www.sec.gov

Donald J. Hayden, Jr., A.N. "Jerry" Karabelas, Ph.D. and Daniel Tassé are the three Class II directors whose terms expire at this Annual Meeting.
Hayden and Tassé and Dr. Karabelas have been nominated for election by the Board to serve until the 2020 annual meeting of stockholders or until their successors are elected (or until their earlier death, resignation or removal). Hayden and Tassé and Dr. Karabelas to the Board at the Annual Meeting, unless otherwise marked on the card. Hayden and Tassé and Dr. Karabelas, the Company's three director nominees, have each agreed to serve as a director if elected. Donald J. Hayden, Jr. Donald J. Hayden, Jr. has been a Director and Chairman of the Board since February 2013. From 1991 to 2006, Mr. Hayden held several executive positions with Bristol-Myers Squibb Company, a biopharmaceutical company, most recently serving as Executive Vice President and President, Americas. Mr. Hayden has served as Chairman of the board of directors at Insmed Incorporated, a publicly held biopharmaceutical company, since December 2010, Lead Independent Director at Amicus Therapeutics, Inc. ("Amicus"), a publicly held biotechnology company, since February 2010 and a director at Amicus since March 2006. He also has served as a director at Otsuka America Pharmaceutical, Inc., a privately held U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., since January 2010 and WindMIL Therapeutics, Inc., a privately held biotechnology company, since January 2017. Mr. Hayden served as Chairman of the board of directors at Vitae Pharmaceuticals, Inc. from March 2006 to October 2016, and as a director at Dimension Therapeutics, Inc., a gene therapy company, from Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University. Mr. Hayden has specific attributes that qualify him to serve as a member of the Board, including his broad experience in the biotechnology and pharmaceutical industry, his service chairing public and private company boards, his experience helping shape new technologies, products and markets and his experience leading health care businesses in the United States and internationally. The Board determined that Donald J. Hayden, Jr. became independent during the fourth quarter of 2016. Information Regarding the Board of Directors and its Committees As required under NASDAQ listing standards, our independent directors meet in regularly scheduled executive sessions at which only independent directors are present, noting that we have relied on Nasdaq Marketplace Rule 5615(b)(1), a "phase-in" rule for companies following their initial public offerings, in allowing Mr. Hayden to be present and preside over these executive sessions prior to the Board determining that Mr. Hayden became independent during the fourth quarter of 2016. Donald J. Hayden, Jr. Mr. Hayden resigned as Chairman and a member of the Compensation Committee effective September 12, 2016 and Mr. Hayden was reappointed as Chairman and a member of the Compensation Committee effective November 1, 2016. Three directors comprised the Compensation Committee of the Board as of December 31, 2016: Mr. Hayden (the Chairman of the Compensation Committee), Mr. Beshar and Mr. Tassé. Mr. Hayden qualified as an independent director in accordance with the rules of NASDAQ commencing during the fourth quarter of 2016. We were permitted to phase-in our compliance with the independent compensation committee requirements set forth in the rules of NASDAQ and the Exchange Act, which would require the compensation committee to be compromised of all independent members within one year of listing. Effective September 12, 2016, which was within one year of our listing on NASDAQ, Mr. Hayden resigned from our Compensation Committee. Effective November 1, 2016, the Board determined that Mr. Hayden qualified as an independent director and Mr. Hayden was reappointed as Chairman and a member of our Compensation Committee.


Board of Directors - Vitae Pharmaceuticals

vitaepharma.com [cached]

Donald Hayden, Jr. has served as a member of our board of directors since 2006 and the Chairman of the board of directors since 2006.
Mr. Hayden previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed, a biotechnology company. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. Mr. Hayden currently serves as lead independent director of Amicus Therapeutics Inc., a biopharmaceutical company, and as non-Executive Chairman of the board of directors of Insmed. Mr. Hayden is also a director of Otsuka America Pharmaceuticals, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited, a manufacturer of pharmaceuticals and nutraceutical products. Mr. Hayden also serves on the boards of directors for four privately-held companies: Alvine Pharmaceuticals; Nora Therapeutics; ReGenX Biosciences; and Dimension Therapeutics. Mr. Hayden is also a senior advisor to Prospect Venture Partners, a venture capital firm. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Masters of Business Administration degree from Indiana University. Mr. Hayden's qualifications to sit on our board include his extensive leadership, executive, managerial and business experience with life sciences companies, including experience in the formation, development and business strategy of multiple start-up companies in the life sciences sector.


Prospect Venture Partners :: Donald J. Hayden, Jr.

www.prospectventures.com [cached]

Donald J. Hayden, Jr.
Don Hayden is a Senior Advisor to Prospect Venture Partners. Mr. Hayden brings to Prospect the experiences and perspective resulting from a highly-successful 25 year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5 years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.


Board of Directors - REGENXBIO

www.regenxbio.com [cached]

Don Hayden
Chairman of the Board Don Hayden brings experience and insight to the REGENXBIO Board. Mr. Hayden had a highly successful 25-year career with Bristol-Myers Squibb Company and continues to hold key roles at a number of entrepreneurial pharmaceutical and biotech companies. At Bristol-Myers Squibb, he served as president of Global Pharmaceuticals; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group; president of Oncology and Immunology; and senior vice president for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, he has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals, Nora Therapeutics, and Dimension Therapeutics. Mr. Hayden received an M.B.A. from Indiana University and his undergraduate degree from Harvard University.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory